Search

Meeting program

Thursday, October 12*All times are in EET.

Read more

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

Read more

Major changes needed for patients to benefit from precision medicine

Precision medicine approaches the treatment of a disease via an individual’s genes, environment, and lifestyle.

Read more

Lymphoma, multiple myeloma and marrow failure syndromes better understood during Sri Lanka tutorial

Hematologists from Sri Lanka and surrounding countries learned how to best care for patients with lymphoma, multiple myeloma and bone marrow failure syndromes and stem cell transplantation during the joint Tutorial organized by EHA with the Sri Lanka College of…

Read more

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

David Grimwade Award

In 2017, EHA established a new award in honor of the late David Grimwade, for his great involvement and contribution to the European Hematology Association and its scientific activities as Board Member, TRTH Co-Director and Chair of the Scientific Program…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more